A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Clinical trial NCT01320085 · COMPLETED

Trial details

NCT number: NCT01320085
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

BRAF or NRAS Mutant Metastatic Melanoma

Start date: 2011-03-24
Primary completion: 2014-01-07
Enrollment: 183

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.